Trial reportDrug design, development and therapy2026
ED95 of Liposomal Bupivacaine for Postoperative Local Infiltration Analgesia in Women Undergoing Cesarean Section: A Randomized Controlled Trial.
Trial report in Drug design, development and therapy, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background: At present, the median effective dose (ED50) and effective dose for 95% of patients (ED95) of liposomal bupivacaine for local infiltration analgesia following cesarean section have not been established. This study aimed to determine the ED95 of liposomal bupivacaine for local infiltration analgesia in patients following cesarean section. Methods: A total of 72 primiparas scheduled to undergo lower segment cesarean sections, were randomly divided into four groups: Group 1, Group 2, Group 3, and Group 4, with 18 cases in each group. When suturing to the fascial layer, the four groups received 66.5 mg, 133 mg, 199.5 mg, and 266 mg of liposomal bupivacaine for incision infiltration analgesia, respectively. The pain intensity at coughing was assessed using a visual analog scale (VAS) within 48 hours postoperatively. Effective analgesia was defined as a VAS score of ≤ 3. The ED95 and the 95% confidence interval (CI) of liposomal bupivacaine for local infiltration analgesia after cesarean section were calculated using probit regression analysis. Results: The ED50 and ED95 of liposomal bupivacaine for local infiltration analgesia following cesarean section were 128.5mg (95% CI, 106.8 to 194.4mg) and 206.1 (95% CI, 178.6 to 262.5mg), respectively. Conclusion: This study indicated that the ED95 of liposomal bupivacaine for local infiltration analgesia following cesarean section was 206.1 mg (95% CI, 178.6, 262.5 mg). (registration number: ChiCTR2300076315).
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.